From July 1, 2022 to September 30, 2022, the company has repurchased 246,000 shares, representing 0.38% for DKK 637.63 million. With this, the company has completed the repurchase of 570,000 shares, representing 0.87% for DKK 1,354.49 million under the buyback announced on March 1, 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,954 DKK | +2.04% | -2.01% | -9.30% |
Apr. 16 | Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug | MT |
Apr. 16 | Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.30% | 17.85B | |
-2.31% | 103B | |
+0.56% | 95.71B | |
+1.69% | 22.02B | |
-17.37% | 20.9B | |
-41.01% | 16.21B | |
-14.85% | 15.52B | |
+3.21% | 13.86B | |
+33.54% | 12.04B | |
-24.71% | 8.08B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Tranche Update on Genmab A/S's Equity Buyback Plan announced on March 1, 2021.